Rebecca Cohen

Years Active: 2022-2022
Publications (10 Years): 1

This page only lists publications with an associated author ORCID identifier.

Publications

Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, Luckson N Mathieu, Yi Ren, Joyce Cheng, Mallorie H Fiero, Wentao Fu, Youwei Bi, Shyam Kalavar, Samina Jafri, Pallavi S Mishra-Kalyani, Jeanne Fourie Zirkelbach, Hongshan Li, Hong Zhao, Kun He, Whitney S Helms, Meredith K Chuk, Min Wang, Ilynn Bulatao, Jonathan Herz, Blaire L Osborn, Yuan Xu, Jiang Liu, Yutao Gong, Sharon Sickafuse, Rebecca Cohen, Martha Donoghue, Richard Pazdur, Julia A Beaver, Harpreet Singh
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (11) (2022)

Rebecca Cohen.css-eqlu8i{font-size:small;padding-left:4px;}